Development and validation of a dissolution method with spectrophotometric analysis for diacerhein capsules

Scientia Pharmaceutica

Volumn 76, Issue 3, 2008, Pages 541-554

  Borgmann, Silvia H M ^a   Parcianello, Lutiane ^b   Arend, Marcela Z ^b   Bajerski, Liziane ^b   Cardoso, Simone G ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Diacerhein capsules; Dissolution; Validation

Indexed keywords

DIACETYLRHEIN;

ARTICLE; DISSOLUTION; DRUG CAPSULE; DRUG SOLUBILITY; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION PROCESS;

EID: 52449100143     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0804-17     Document Type: Article

References (34)

1. The Merck Index. 2001 an Encyclopaedia of Chemicals, Drugs and Biologicals. Merck & CO., INC. Whitehouse Station, NJ.
2. Tamura, T; Ohmori, K. Rhein, an Active Metabolite of Diacerhein, Suppresses the lnterleukin-1 a Induced Proteoglycan Degradation in Cultured Rabbit Articular Chondrocytes. Jpn J Pharmacol. 2001; 85: 101-104. [doi:10.1254/jjp.85.101]
3. Spencer, CM, Wilde MC. Diacerein. Drugs. 1997;53:98-106. [doi:10.2165/00003495-199753010-00007]
4. Tamura, T, Shirai, T, Kosaka, K, Ohmori, K, Takafumi, T. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol. 2002; 448: 81-87. [doi:10.1016/S0014-2999(02)01898- 8]
5. Mendes, AF, Caramona, MM, Carvalho, AP, Lopes, MC. Diacerhein and Rhein Prevent lnterleukin-13-lnduced Nuclear Factor-KB Activation by Inhibiting the Degradation of Inhibitor kB-α. Pharmacol Toxicol. 2002; 91: 22-28. [doi:10.1034/j.1600-0773.2002.910104.x]
6. Lequesne, M. Symptomatic slow acting drugs in osteoarthritis: a novel therapeutic concept? Rev Rhum. 1994;61:69-73.
7. Mahajan, A, Singh, K, Tandon, VR, Kumar, S, Kumar, H. Diacerein: A new symptomatic slow acting drug for osteoarthritis. JK Science. 2006; 8: 173-175.
8. Pomarelli, P. A non steroidal anti-inflammatory drug that stimulates prostaglandin release. Farmaco. 1980; 35: 836-842.
9. Franchi-Micheli, S. The influence of rhein on the biosynthesis of prostaglandin-like substances invitro. J Pharm Pharmacol. 1983. 35: 262-264.
10. Pujol, JP, Felisaz, N, Boumediene, K, Ghayon, C, Herrouin, JF, Bogdanowics, P, Galera, P. Collagenolytic enzymes and interleukin-1: their role in inflammation and cartilage degradation. The antagonist effects of diacerhein on IL-1 actions on 99 cartilage matrix components. Biorh. 2000; 37: 177-184.
11. Pelletier, JP. Diacerhein and Rhein reduce the interleukin 1b stimulates inducible nitric oxid synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998; 25: 2417-2424.
12. Emami, J. In vitro - In vivo Correlation: from theory to Applications. J Pharm Pharm Sci. 2006; 9: 169-189.
13. FDA (1997) Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Food and Drug Administration, Rockville MD.
14. Giannellini, V, Salvatore, F, Bartolucci, G, Coran, SA, Alberti, MB. A validated HPLC-stability-indicating method for the determination of diacerhein in bulk drug substance. J Pharm Biomed Anal. 2005; 39: 776-780. [doi:10.1016/j.jpba.2005.04.040]
15. Borgmann, SHM, Parcianello, L, Arend, MZ., Cardoso, SG. Direct spectrophotometric determination of diacerhein in capsules. Pharmazie. 2007; 62: 483-485. [doi:10.1691/ph.2007.7.6263]
16. Menegola, J., Steppe M., Schapoval, EES. Dissolution test for citalopram in tablets and comparison of in vitro dissolution profiles. Eur J Pharm Biopharm. 2007; 67: 524-530. [doi:10.1016/j.ejpb.2007.02.009]
17. Breier, AR, Paim, CS, Stepe, M., Schapoval, EES. Development and validation of dissolution tests of fexofenadine hydrochloride capsules and coated tablets. J Pharm Pharm Sci. 2005; 8: 289-298.
18. Cardoso, SG, Bajerski, L, Malesuik, MD, Dorfey, B. Development of dissolution method and comparative study of pharmaceutical solid forms containing cetirizine. Lat Am J Pharm. 2007; 26: 108-114.
19. Malesuik, MD, Cardoso, SG, Lanzanova, FA, Bajerski, L, Dorigoni, E. Development of dissolution test and comparative study of tablets and compounded capsules containing amlodipine. Rev Cienc Farm Basica Apl. 2006; 27: 37-49.
20. Rossi, RC, Dias, CL, Donato, EM, Martins, LA, Bergold, AM, Fröehlich, PE. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data. Int J Pharm. 2007; 338: 119-124. [doi:10.1016/j.ijpharm.2007.01.036]
21. Rolim, CMB, Brum Jr, L, Fronza, M, Malesuik, MD, Bajerski, L, Dalmora, SL. Development and validation of an RP-HPLC method for the dissolution studies of bisoprolol in pharmaceutical dosage forms. J Liq Chromatogr Related Technol. 2005; 28: 477-486. [doi:10.1081/JLC-200044531]
22. Fronza, M, Brum Jr, L, Wrasse, M, Barth, T, Dalmora, SL. Development and validation of a RP-HPLC method for the quantitation and dissolution studies of valdecoxib. Acta Pharm Bonae. 2006; 25: 117-122.
23. The United States Pharmacopoeia (2007) 31th Ed., United States Pharmacopoeial Convention, Rokville.
24. Pharmacopeial Fórum (2004). Pharmacopeial Previews, 30.
25. Shah, VP, Lesko, LJ, Fan, Fleischer, J, N, J. Handerson, Malinowski, H, Makary, M, Ouderkirk, L, Roy, S, Sathe, P, Singh, GJP, Tillman, L,Tsong Y, Williams, RL. FDA guidance for industry: dissolution testing of immediate release solid oral dosage forms. Dissolution Technol. 1997; 4: 15-22.
26. Moore, JW, Flanner, HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996; 20: 64-74.
27. Khan, KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975; 28: 48-49.
28. ICH - Q2 (R1) (2005) Guideline on Validation of Analytical Procedure. Text and Methodology,
29. Azarmi, S, Roa, W, Löbenberg, R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm. 2007; 328: 12-21. [doi:10.1016/j.ijpharm.2006.10.001]
30. Brown, CK, Chokshi, HP, Nickerson, B, Reed, RA., Rohrs, BR, Shah, PA. Acceptable analytical practices for dissolution testing of poorly soluble compounds. Pharm Technol. 2004; 28: 56-65.
31. Noory, C, Tran, N, Ouderkirk, L, Shah, V. Steps for development of dissolution test for sparling water-soluble drug products. Dissolution Technol. 2000; 7: 16-19.
32. Wang, Q, MA, D, Higgins, JP. Analytical Method for drug product dissolution testing. Dissolution Technol. 2006; 13: 6-13.
33. Fortunato, D. Dissolution Method Development for Immediate Release Solid Oral Dosage Forms. Dissolution Technol. 2005; 12: 12-14.
34. Wade, A, Weller, PJ, (1994) Handbook of Pharmaceutical Excipients, 2nd Ed.